Gianni L, Huang CS, Egle D, Bermejo B, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study. Ann Oncol 2022 Feb 16. pii: S0923-7534(22)00113.
PMID: 35182721